Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Alkylating Antineoplastic Agents. Found 11 abstracts

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 Sep;29(9):1995-2002.   PMCID: PMC6454486
Zijoo R, von Mehren M. Efficacy of trabectedin for the treatment of liposarcoma. Expert Opin Pharmacother. 2016 Oct;17(14):1953-62.
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002 Jun 15;62(12):3377-81.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs. 2002 May;13 Suppl 1:S3-6.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001 Jul 15;61(14):5491-8.
Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys. 2000 Dec;48(5):1351-8.
Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res. 2000 Apr;6(4):1314-21.
Rosario LA, O'Brien ML, Henderson CJ, Wolf CR, Tew KD. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol. 2000 Jul;58(1):167-74.
Ma J, Fei ZL, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis. 1998 Aug;16(6):559-68.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Alkylating Antineoplastic Agents

Alkylating Antineoplastic Agents drug therapy pharmacology Human Male Dacarbazine Cultured Tumor Cells US Gov't Support-PHS Female analogs & derivatives metabolism therapeutic use Animal Antitumor Drug Screening Assays Dioxoles Middle Aged pharmacokinetics drug effects pathology mortality Rats blood Adult Cyclins Glioblastoma Isoquinolines Drug Interactions Young Adult Aged Carmustine adverse effects Non-US Gov't Support Combined Modality Therapy Glioma Glutathione genetics Nude Rats Brain Neoplasms radiotherapy physiology Leiomyosarcoma Neoplasm Proteins Liposarcoma Epidermal Growth Factor Receptor Adenosinetriphosphatase Inhibitory Concentration 50 Colonic Neoplasms Neoplasms metastatic liposarcoma trabectedin Monoclonal Antibodies blood supply Glutathione Transferase me [Metabolism] 73-40-5 (Guanine) Dialysis Solutions Heterologous Transplantation Adolescent Phytogenic Antineoplastic Agents Xenograft Model Antitumor Assays Phenotype derivatives Kaplan-Meier Estimate Microdialysis Intravenous Infusions pd [Pharmacology] Sulfhydryl Compounds Homocysteine Phytogenic) 0 (Antineoplastic Agents immunology de [Drug Effects] 0 (Proto-Oncogene Proteins c-bcl-2) Oxidation-Reduction Transfection administration & Kaplan-Meiers Estimate 0 (cyclin-dependent kinase Inhibitor p21) Cell Cycle human) EC 3-6-1 (PMS2 protein Acetaldehyde MDR Genes analogs & EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) 85622-93-1 (temozolomide) O(6)-Methylguanine-DNA Methyltransferase Alkylating) 0 (Antineoplastic Agents Angiogenesis Inhibitors urine Cysteine 0 (Cyclins) Tetrahydroisoquinolines Multiple Drug Resistance Drug Dose-Response Relationship Et-743 Radioimmunotherapy Antisense DNA Capillaries Protein p53 Age Factors 3T3 Cells Pathologic Neovascularization Prodrugs Multivariate Analysis Cytotoxins 33069-62-4 (Paclitaxel) 80 and over Aged 23214-92-8 (Doxorubicin) mammalian) 0 (MLH1 protein Trabectedin aa [Analogs & Derivatives] 4342-03-4 (Dacarbazine) Leukocytes Dose Fractionation Ifosfamide Intravenous Administration Experimental Neoplasms liposarcoma chemistry Trans-Activation (Genetics) Doxorubicin Disease-Free Survival 19916-73-5 (O(6)-benzylguanine) 0 (Protein p53) CCAAT-Binding Factor ph [Physiology] Lymphokines administration & dosage Mice Adjuvant Radiotherapy 0 (DNA-Binding Proteins) Proportional Hazards Models Protective Agents dosage DNA Repair Enzymes bi [Biosynthesis] Genetic Vectors Proto-Oncogene Proteins c-bcl-2 EC 3-6-1-3 (Adenosinetriphosphatase) Sarcoma unresectable liposarcoma Time Factors Sesquiterpenes Drug Administration Schedule Paclitaxel Guanine pa [Pathology] DNA-Binding Proteins Prospective Studies soft tissue sarcoma Sp1 Transcription Factor
Last updated on Wednesday, March 04, 2020